|
Michael Weiser M.D. Ph.D. has been a director of the Hana since its inception. Dr. Weiser is currently founder and co-chairman of Actin Capital LLC and Actin Biomed a New York based healthcare investment firm advancing the discovery and development of novel treatments for unmet medical needs. Prior to joining Actin Dr. Weiser was the Director of Research at Paramount BioCapital where he was responsible for the scientific medical and financial evaluation of biomedical technologies and pharmaceutical products under consideration for development. Dr. Weiser completed his Ph.D. in Molecular Neurobiology at Cornell University Medical College and received his M.D. from New York University School of Medicine. He performed his post-graduate medical training in the Department of Obstetrics and Gynecology at New York University Medical Center. Dr. Weiser also completed a Postdoctoral Fellowship in the Department of Physiology and Neuroscience at New York University School of Medicine and received his B.A. in Psychology from University of Vermont. Dr. Weiser is a member of The National Medical Honor Society Alpha Omega Alpha. In addition Dr. Weiser has received awards for both academic and professional excellence and is published extensively in both medical and scientific journals. Dr. Weiser currently serves on the board of directors of Manhattan Pharmaceuticals Inc Chelsea Therapeutics International Ltd. Emisphere Technologies Inc. Hana Biosciences Inc. Ziopharm Oncology Inc. Vioquest Pharmaceuticals Inc. and Paramount Acquisition Corp. as well as several privately held companies. | 